# Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)

> **NCT00249834** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 166 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** Gonal-f
- **DRUG:** Recombinant human chorionic gonadotrophin (r-hCG)

## Key facts

- **NCT ID:** NCT00249834
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-22
- **Primary completion:** 2006-01-16
- **Final completion:** 2006-01-16
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2018-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249834, "Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00249834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*